8-KItem 1.02 · Termination of AgreementItem 9.01 · Financial Statements
Amgen filed a Termination Agreement with Kyowa Kirin dated Jan 30, 2026 (Exhibit 10.1).
Filed with the SEC on · Summarized by InvestorsBot
Amgen filed a Termination Agreement with Kyowa Kirin dated Jan 30, 2026 (Exhibit 10.1). Portions of the exhibit are redacted as confidential; 8‑K discloses no material deal terms. 📄 $AMGN #SECfiling #Biotech
8‑K contains no financial terms — the termination may affect Amgen’s collaboration/licensed assets with Kyowa Kirin. Investors should monitor for follow‑up disclosures on commercial or pipeline impact. 🔍 $AMGN #Investing #DrugDev
Filing signed Jan 30, 2026 by Jonathan P. Graham, EVP & General Counsel; interactive XBRL cover page included. Expect additional disclosures if material impacts arise. ✍️ $AMGN #AMGN #SECfiling